EMA grants orphan drug status to OctreoPharm’s SOMscan
The European Medicines Agency (EMA) has granted orphan drug status to OctreoPharm Sciences' SOMscan, used for the diagnosis of gastro-entero-pancreatic neuroendocrine tumours.
The European Medicines Agency (EMA) has granted orphan drug status to OctreoPharm Sciences’ SOMscan, used for the diagnosis of gastro-entero-pancreatic neuroendocrine tumours.
The new Gallium-68-labeled radioactive contrast agent for PET has the potential to detect Phase I neuroendocrine tumours.
SOMscan binds to four out of five specific tumour receptor subtypes, which may allow detection of tumours that previously escaped discovery in imaging.
Sign up for our daily news round-up!
Give your business an edge with our leading industry insights.
Medical Device Network Excellence Awards - Nominations Closed
Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact
Excellence in Action SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.
